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PR ESEN TATION OF C A SE
Dr. Celine R. Gounder (Department of Medicine): A 79-year-old woman was admitted 
to the hospital because of myalgias, fatigue, and shortness of breath.
Hyperlipidemia had been diagnosed six years earlier and had been controlled 
with simvastatin. Three years before admission, treatment with simvastatin was 
discontinued because of myalgias, and atorvastatin was started. Seven months be-
fore admission, pain developed over the lateral aspect of the chest wall bilaterally, 
extending from the axillas to the middle of her rib cage. The area was sore to the 
touch, but the pain was not affected by activity or changes in position. It did not 
awaken her from sleep. She also felt a lump in her throat when swallowing and 
had pain that radiated to her right ear. She discontinued atorvastatin, and the 
symptoms gradually resolved. One to two months later, she resumed atorvastatin, 
and the symptoms recurred, along with fatigue and reduced tolerance for exercise. 
Because of this, one month before admission, ezetimibe was added to her medica-
tions, and the dose of atorvastatin was reduced from 20 mg to 10 mg per day. Two 
days later, bilateral shoulder aches and neck and back pain developed. She stopped 
taking both ezetimibe and atorvastatin, but the symptoms persisted.
Eleven days before admission, she saw her primary care physician. She had what 
she described as “unbearable” pain in the morning and difficulty arising from her 
bed and from chairs, a sore throat, and pain over the lateral aspect of the chest wall 
bilaterally, extending from the axillas to the middle of her rib cage. On examina-
tion, there was normal range of motion of all joints. There was tenderness with 
abduction of the shoulders at about 45 degrees, worse on the left than the right. 
Motor strength was 4+ out of 5+ in all muscle groups of the arms and legs. There 
was no muscle tenderness. The results of liver- and renal-function tests and the 
levels of serum electrolytes, creatine kinase, aldolase, and aminotransferase were 
normal. Hematologic test results are shown in Table 1.
During the next week, the pain and fatigue persisted, and weakness worsened. 
The patient reported continuing difficulty arising from a chair and difficulty comb-
ing her hair. She did not have headaches, visual changes, jaw claudication, difficulty 
chewing food, fevers, night sweats, or a change in weight. Four days before admis-
sion, she again saw her primary care physician, who documented increased proximal 
muscle weakness; the findings on physical examination were otherwise unchanged. 
Case 4-2006: A 79-Year-Old Woman with 
Myalgias, Fatigue, and Shortness of Breath
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Prednisone was started at a dose of 20 mg per 
day. The pain and weakness improved, but two 
days before admission progressively worsening 
shortness of breath developed with minimal exer-
tion and with prolonged speaking. She did not 
have chest pain or palpitations. She was admitted 
to this hospital.
The patient had had a myocardial infarction 
six years before admission that had required 
placement of a stent in the right coronary artery. 
Ten years before admission, a diagnosis of breast 
cancer had been made; the cancer had been treat-
ed by lumpectomy and radiation therapy, with no 
recurrence. The patient had had several admis-
sions to the hospital for management of pancre-
atitis and pseudocyst formation. Eight months 
before admission, an endoscopic ampullectomy 
had been performed for treatment of an ampul-
lary adenoma. Six weeks before admission, an 
episode of atrial fibrillation occurred, which was 
controlled with metoprolol. A cardiac ultrasono-
graphic examination at that time showed trace 
mitral regurgitation and an ejection fraction of 
67 percent.
There was a history of anxiety, depression, 
osteoarthritis, and gastroesophageal reflux. The 
patient’s mother and an aunt had had breast can-
cer; her father and two brothers had had coro-
nary artery disease, and a sister had died of lung 
cancer. She was a retired widow who lived alone; 
a son and daughter were well. She had never 
smoked, and she drank alcohol rarely. Her medi-
cations on admission were prednisone, aspirin, 
venlafaxine, esomeprazole, lorazepam, ranitidine, 
and metoprolol.
On physical examination, the patient was alert 
and in no distress. The temperature was 36.7°C, 
the blood pressure 130/70 mm Hg, and the pulse 
78 beats per minute with a regular rhythm; the 
respiratory rate was 16 breaths per minute. The 
head and neck appeared to be normal without 
areas of tenderness; the temporal arteries were 
not palpable or tender. There was no cervical or 
axillary lymphadenopathy. Inspiratory crackles 
were heard at both lung bases. The heart sounds 
were normal without murmurs. The abdomen was 
soft and nontender without masses or organo-
megaly. There was pitting edema (+) of the legs 
extending proximally to 3 cm below the knees. 
The peripheral pulses were easily felt, and the 
distal extremities were warm. The motor strength 
was rated 5 out of 5 in all muscle groups. An 
electrocardiogram demonstrated a normal sinus 
rhythm with a rate of 90 beats per minute and 
Q waves in leads II, III, and aVF. A chest radio-
graph demonstrated patchy bibasilar atelectasis. 
Hematologic laboratory results are listed in Ta-
ble 1. Her symptoms improved over the next two 
days while she was receiving the same dose of 
prednisone, and she was discharged on the third 
hospital day.
Shortly after discharge, the patient’s sore throat 
and hoarseness recurred. A diagnostic procedure 
was performed one week later.
DIFFER EN TI A L DI AGNOSIS
Dr. Nancy Lee Harris (Pathology): Dr. Finn will give 
us the general internist’s perspective on this case.
Dr. David S. Finn: This patient initially presented 
to my office with generalized muscle aches. She 
had a known history of coronary artery disease; 
her low-density lipoprotein cholesterol level was 
above 70 mg per deciliter (1.80 mmol per liter), 
Table 1. Hematologic Laboratory Values.
Variable 11 Days before Admission On Admission Normal Range
White-cell count (per mm3) 7,400 9,400 4,500–11,000
Hematocrit (%) 35.2 34.4 36.0–46.0
Hemoglobin (g/dl) 11.4 11.5 12.0–16.0
Red cells (per mm3) 3,850,000 3,880,000 4,000,000–5,200,000
Platelet count (per mm3) 360,000 402,000 150,000–350,000
Mean corpuscular volume (μm3) 92 89 80–100
Mean corpuscular hemoglobin (pg/cell) 29.7 29.6 26.0–34.0
Mean corpuscular hemoglobin concentration (g/dl) 32.4 33.4 31.0–37.0
Erythrocyte sedimentation rate (mm/hr) 90 Unavailable Unavailable
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and she had not been able to tolerate doses of 
atorvastatin greater than 10 to 20 mg in the past; 
these doses caused myalgias with normal creatine 
kinase levels. One week before her presentation at 
my office, ezetimibe, at a dose of 10 mg per day, 
had been added to her regimen in accordance with 
the 2004 National Cholesterol Education Program 
guidelines.1
The patient had stopped taking the ezetimibe 
several days before the office visit after reading 
the package insert, which listed all her symptoms 
as possible side effects from the medication. An 
examination revealed mild weakness of the up-
per and lower extremities that was greater proxi-
mally than distally. There was no synovitis on 
examination, and she had full range of motion 
of all her joints without pain. The initial inter-
vention was to continue to withhold her lipid-
lowering medications, on the assumption that 
these were responsible for her symptoms.
The incidence of statin-associated myalgias 
ranges from 1 to 5 percent in the randomized, 
controlled trials in which the symptom is report-
ed.2 This level did not differ markedly from that 
of placebo in most trials. This small percentage, 
however, is in vast contrast to the clinical experi-
ence; 25 percent or more of patients in surveil-
lance databases report myalgias, with the average 
between 5 to 10 percent.2 The cause of this large 
discrepancy between the clinical-trial experience 
and the outpatient-practice experience is unclear, 
but there is some evidence that patients can have 
a statin-associated myopathy with normal levels 
of creatine kinase.3 Ezetimibe has also been re-
ported to cause myalgias in up to 4 percent of 
patients, and there have been additional case re-
ports of myositis associated with the combination 
of atorvastatin and ezetimibe.4
My initial differential diagnosis also included 
polymyalgia rheumatica, temporal arteritis, a viral 
infection, subacute bacterial endocarditis, hypo-
thyroidism, inflammatory arthritis, and even a re-
currence of breast cancer in the form of a para-
neoplastic syndrome. A recent test showed a 
normal level of thyroid-stimulating hormone. I 
ordered routine laboratory tests, and the patient 
was instructed to return to the office in one week. 
At the time of her return, she had increased weak-
ness, much greater proximally than distally, as 
well as fatigue. On examination, there was in-
creased proximal muscle weakness, but no other 
abnormalities were evident, and no abnormality 
was noted on palpation of the temporal arteries. 
The laboratory-test results were normal except for 
an elevated erythrocyte sedimentation rate and a 
decrease in the hematocrit from her usual level 
of 38 percent to 35 percent. The combination of 
her symptoms, her elevated sedimentation rate, 
and the general lack of an alternative cause led me 
to a diagnosis of polymyalgia rheumatica.
I prescribed 20 mg per day of prednisone, with 
the expectation that the patient would have a 
dramatic improvement in her symptoms over the 
next 48 to 72 hours. When I spoke with her on 
the telephone four days later, she reported that the 
myalgias had improved, but increasing dyspnea 
had developed, to the extent that she was unable 
to perform her activities of daily living.
At this point, she clearly had a systemic inflam-
matory condition with fatigue, weakness, dyspnea, 
pharyngitis, elevated inflammatory markers, and 
a new anemia. Although she did not have many 
of the typical symptoms of giant-cell arteritis 
(headache, jaw claudication, and visual changes), 
many patients do not present with typical symp-
toms, and 4 percent of patients pre sent with 
chiefly respiratory symptoms. Although the pa-
tient had some improvement while taking low-
dose corticosteroids, it was not the dramatic im-
provement I had expected to see in a patient with 
polymyalgia rheumatica. The alternative diagno-
ses (subacute bacterial endocarditis, cancer, and 
other infections) all seemed unlikely. I began to 
suspect the diagnosis of giant-cell arteritis and 
admitted her to the hospital for further evaluation. 
I asked for consultation from the rheumatology 
service.
Dr. Jonathan Kay: This 79-year-old woman pre-
sented with fatigue and the relatively sudden on-
set of bilateral shoulder, neck, and back pain, 
which were most pronounced on awakening and 
did not improve with discontinuation of ezetimibe 
and atorvastatin. She experienced difficulty aris-
ing from chairs but had normal levels of muscle 
enzymes, suggesting that her symptoms were not 
due to a primary myopathic process. However, she 
had a mild anemia, and her erythrocyte sedimen-
tation rate was markedly elevated at 90 mm per 
hour. Four days before admission, she had been 
started on oral prednisone (20 mg daily).
Her clinical presentation is typical of polymy-
algia rheumatica, for which two sets of diagnostic 
criteria have been formulated empirically — by 
Chuang et al.5 and Healey.6 Both sets of criteria 
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require the presence of pain and stiffness per-
sisting for at least one month and involving two of 
the following areas: neck, shoulders, and pelvic 
girdle. Patients must be 50 years of age or older 
and have an erythrocyte sedimentation rate el-
evated to more than 40 mm per hour. All other 
diseases that might cause these musculoskeletal 
symptoms, other than giant-cell arteritis (which 
can be associated with polymyalgia rheumati-
ca), must be ruled out. In addition, Healey’s diag-
nostic criteria require a rapid response to pred-
nisone therapy at a daily dose no higher than 
20 mg; despite some initial improvement, this pa-
tient’s symptoms worsened while she received 
this therapy.
What other conditions might cause this wom-
an’s musculoskeletal symptoms? As Dr. Finn has 
mentioned, statin drugs may cause a painful my-
opathy, but there was no elevation of the level of 
muscle enzymes and her symptoms did not im-
prove with the discontinuation of her lipid-low-
ering medications. Idiopathic inflammatory my-
opathies, such as polymyositis, dermatomyositis, 
and inclusion body myositis, also would be ac-
companied by elevated levels of muscle enzymes 
and usually by painless muscle weakness. About 
15 percent of patients with rheumatoid arthritis 
present with polymyalgia rheumatica, with neck, 
shoulder, and pelvic-girdle pain and stiffness. 
However, this patient had no joint swelling or 
tenderness. Patients with degenerative arthritis 
may perceive pain above or below involved joints, 
but the morning stiffness that this woman had is 
more characteristic of an inflammatory process.
A patient with hypothyroidism may present 
with fatigue and muscle pain. However, these 
clinical manifestations usually are accompanied 
by elevated levels of muscle enzymes and other 
features of hypothyroidism, such as abnormal re-
flexes, low levels of thyroid hormone, and elevat-
ed levels of thyroid-stimulating hormone. Patients 
with fibromyalgia and other diffuse pain syn-
dromes — which often accompany sleep disor-
ders,7 depression,8 and past physical or sexual 
abuse9 — may present with fatigue and neck, 
shoulder, and pelvic-girdle pain and stiffness that 
are more pronounced on awakening. However, 
patients with hypothyroidism or diffuse pain syn-
dromes also perceive pain in other areas and usu-
ally do not have anemia or a marked elevation of 
the erythrocyte sedimentation rate.
With this woman’s history of breast cancer, 
one must take into consideration that her neck, 
shoulder, chest-wall, and low-back pain might her-
ald metastatic breast cancer. Furthermore, some 
cancers may be accompanied by a paraneoplastic 
syndrome that resembles polymyalgia rheumati-
ca, with an elevation of the erythrocyte sedimen-
tation rate that is associated with the pres ence of 
the cancer.10 However, the onset of polymyalgia 
rheumatica is often so sudden that the patient may 
recall the exact date when symptoms first began, 
whereas that of a paraneoplastic syndrome mim-
icking polymyalgia rheumatica is much more 
gradual. The most reliable feature that differen-
tiates polymyalgia rheumatica from a paraneoplas-
tic syndrome is the response to therapy: patients 
with polymyalgia rheumatica usually experience 
marked and rapid improvement of their pain 
within four to five days of beginning treatment 
with daily oral prednisone at doses of 20 mg or 
less, whereas those with underlying malignant 
tumors do not have improvement until the can-
cer is treated successfully.
Giant-cell arteritis and polymyalgia rheumatica 
are part of a single disease spectrum. Patients with 
giant-cell arteritis and polymyalgia rheumatica 
have a low frequency of the HLA-DRB1*01 allele. 
As with rheumatoid arthritis, there is an associa-
tion with the HLA-DRB1*04 allele.11 A sequence 
polymorphism in the second hypervariable region 
of the HLA-DR molecule antigen-binding site has 
been identified.12 The disease occurs more com-
monly in people of northern European ancestry 
than in other ethnic groups and may aggregate 
in families.13
This woman reported no constitutional symp-
toms, such as fever, night sweats, or weight loss. 
She reported no headache, visual changes, or jaw 
claudication, which might be symptoms of giant-
cell arteritis, a large-vessel vasculitis that occurs 
in some patients with polymyalgia rheumatica. 
We are told that she had no areas of tenderness 
on her head or neck, nor did she have thickening 
of her temporal arteries, which is a typical physi-
cal sign of giant-cell arteritis. The true prevalence 
of giant-cell arteritis among patients with poly-
myalgia rheumatica is not defined, because pa-
tients presenting with polymyalgia rheumatica do 
not routinely undergo temporal-artery biopsy. In 
one report,14 giant-cell arteritis was demonstrated 
in temporal-artery–biopsy samples from 41 per-
cent of patients with a clinical diagnosis of poly-
myalgia rheumatica. Of these, 47 percent presented 
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without cranial symptoms. Thus, in the setting of 
polymyalgia rheumatica and an elevated erythro-
cyte sedimentation rate, one cannot rely on the 
absence of cranial symptoms to rule out a diag-
nosis of giant-cell arteritis.
Up to 10 percent of patients with giant-cell 
arteritis have pulmonary symptoms.15 This patient 
noted a sore throat; subsequently, progressively 
worsening shortness of breath developed with 
minimal exertion and with prolonged speaking. 
Inspiratory crackles were heard at both lung 
bases and patchy bibasilar atelectasis was evident 
on a chest radiograph. Cough is the most com-
mon presenting pulmonary symptom of giant-cell 
arteritis. Sore throat, presumed to be a symptom 
of ischemia involving the arteries that supply the 
laryngeal and pharyngeal tissues, occurs almost 
as frequently as cough. Peribronchial and inter-
stitial granulomas that have been found in tissue 
obtained by transbronchial lung biopsy from a 
patient with giant-cell arteritis have been inter-
preted as being consistent with pulmonary in-
volvement by giant-cell arteritis.16
The diagnostic procedure in this case should 
have been a temporal-artery biopsy to look for evi-
dence of giant-cell arteritis. Although all attempts 
should be made to perform the temporal-artery 
biopsy before or soon after the initiation of pred-
nisone therapy, findings diagnostic of giant-cell 
arteritis still may be observed even after more than 
14 days of prednisone therapy.17
Dr. Finn: The patient was seen in consultation 
by the surgical service; a temporal-artery biopsy 
was performed.
CL INIC A L DI AGNOSIS
Giant-cell arteritis (temporal arteritis).
DR . JONATH A N K A Y ’S  DI AGNOSIS
Giant-cell arteritis (temporal arteritis).
PATHOL O GIC A L DISCUSSION
Dr. James R. Stone: Histologic examination of the 
biopsy specimen of the temporal artery revealed 
a muscular artery with fragmentation of the in-
ternal elastic lamina, as well as intimal hyperpla-
sia (Fig. 1A). In addition, there was a patchy lym-
phocytic infiltrate in the adventitia (Fig. 1B). 
Careful examination revealed the presence of fo-
cal histiocytic giant cells at the level of the inter-
nal elastic lamina (Fig. 1C). The macrophages at 
this location were also highlighted by immuno-
histochemical staining for the histiocytic marker 
CD68 (Fig. 1D). These findings are diagnostic of 
active giant-cell (temporal) arteritis.
The current approach to the subclassification 
of systemic vasculitis starts with consideration of 
the sizes of the vessels involved.18-20 Large-vessel 
vasculitis often involves the aorta and major ar-
terial branches to the head and arms and legs, 
as well as medium-sized vessels (small to medium-
sized arteries), and is characterized histologically 
by granulomatous inflammation. The primary 
examples are giant-cell arteritis and Takayasu’s 
arteritis. Medium-sized-vessel vasculitis occurs in 
small and medium-sized arteries without the in-
volvement of small vessels (arterioles, capillaries, 
and venules). Primary examples include polyarteri-
tis nodosa and Kawasaki’s disease. Small-vessel 
vasculitis involves small vessels but can also affect 
medium-sized vessels20; examples include diseases 
associated with the antineutrophil cytoplasmic 
antibody (ANCA), such as microscopic polyangi-
itis, Wegener’s granulomatosis, and the Churg–
Strauss syndrome, as well as immune-complex 
vasculitis, that are not associated with ANCA, in-
cluding Henoch–Schönlein purpura, cryoglobulin-
emic vasculitis, drug-induced immune complex 
vasculitis, and immune-complex vasculitis sec-
ondary to infection, cancer, or collagen vascular 
disease.
In the case under discussion, the nature of the 
inflammatory infiltrate and the vessel involved 
are both characteristic of giant-cell arteritis. This 
disease most commonly affects the medium-sized 
extracranial arteries as well as other arteries of 
the head, the aorta and its major branches, and 
the arteries of the arms. Histologically, the con-
dition can usually be identified by the presence 
of a lymphocytic infiltrate in the adventitia or 
media, or both, as well as a granulomatous in-
filtration of macrophages with giant-cell forma-
tion directed at elastic fibers.21 Thus, the giant 
cells will typically be located at the level of the 
internal elastic lamina in muscular arteries such 
as the temporal artery, but they may be dispersed 
throughout the media of elastic arteries and the 
aorta. The intensity and location of these two 
inflammatory components are highly variable 
and do not correlate with clinical symptoms. In 
giant-cell arteritis, in contrast to other forms of 
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vasculitis, necrosis of the vessel wall is not re-
quired for the diagnosis. The infiltrates have been 
shown to persist despite corticosteroid thera-
py.17,22 Fragmentation of the internal elastic lami-
na and intimal hyperplasia are both typically 
present; however, these findings are not by them-
selves diagnostic of arteritis. In giant-cell arteritis, 
arterial occlusion and subsequent ischemia of 
distal tissue typically result from intimal hyper-
plasia and not necessarily from thrombosis, as is 
often found with other forms of vasculitis. Because 
of the segmental nature of the disease, a negative 
biopsy result does not rule out the presence of 
giant-cell arteritis.
Giant-cell arteritis is one of the most common 
types of vasculitis, with an overall clinical preva-
lence of 0.2 percent among people more than 50 
years of age.23 However, autopsy studies have indi-
cated the pathological prevalence to be closer to 
1.7 percent among people in this age group,24 in-
dicating that many cases are subclinical. In fact, 
it is not uncommon for giant-cell arteritis to be 
diagnosed unexpectedly on resection of thoracic 
aortic aneurysms. The cause of this disease is 
not known.
Dr. Harris: Dr. Kay, would you discuss the man-
agement of this patient’s condition?
Dr. Kay: Because not all patients who receive a 
pathological diagnosis of giant-cell arteritis have 
the clinical syndrome, the decision to treat is 
based on a combination of clinical and patho-
logical findings. The diagnostic criteria for the 
A B
C D
Figure 1. Biopsy Specimen of the Temporal Artery.
Panel A shows fragmentation of the internal elastic lamina and intimal hyperplasia (elastic tissue stain). In Panel B, 
lymphocytic infiltration of the adventitia is shown (hematoxylin and eosin). Panel C shows a histiocytic giant cell 
located at the internal elastic lamina (hematoxylin and eosin). In Panel D, immunoperoxidase stain for the macro-
phage marker CD68 shows macrophages at the internal elastic lamina.
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clinical syndrome of giant-cell arteritis include 
three or more of the following: an age of 50 years 
or older at disease onset, new-onset headache, a 
temporal-artery abnormality (tenderness or de-
creased pulse), an erythrocyte sedimentation rate 
of 50 mm per hour or higher, and a temporal-
artery–biopsy specimen showing vasculitis with 
a mononuclear-cell infiltrate or granulomatous 
inflammation, usually with multinucleated giant 
cells. Does this patient without cranial symptoms 
or abnormalities on physical examination meet 
the classification criteria for giant-cell arteritis? 
She was older than 50 years of age, she had an 
elevated sedimentation rate, and her biopsy dem-
onstrated the specific features associated with 
giant-cell arteritis. Thus, we can make a diagno-
sis of the clinical syndrome of giant-cell arteritis.
Whereas polymyalgia rheumatica is effectively 
treated with low doses of oral prednisone, giant-
cell arteritis requires doses of oral prednisone of 
40 to 60 mg, or the equivalent, administered as 
a single or divided daily dose.25 Pulsed intrave-
nous methylprednisolone (1000 mg daily for three 
days) may be given to patients with visual loss.26 
After at least two to four weeks, prednisone may 
be tapered gradually to a maintenance dose that 
controls the associated symptoms of polymyalgia 
rheumatica. Patients with giant-cell arteritis or 
polymyalgia rheumatica may require low-dose 
corticosteroid therapy for several years to con-
trol disease activity. Because of the risk of corti-
costeroid-induced osteoporosis, calcium and vita-
min D supplementation should be administered, 
and consideration should be given to prophylactic 
bi sphosphonate therapy.
A recent randomized, controlled clinical trial27 
demonstrated that low-dose weekly methotrexate 
is an effective corticosteroid-sparing agent for the 
treatment of polymyalgia rheumatica. However, 
low-dose weekly methotrexate is not effective in 
the treatment of giant-cell arteritis.28
Dr. Harris: What causes the pain in patients 
with polymyalgia rheumatica?
Dr. Kay: The pain in polymyalgia rheumatica 
is caused by synovitis. The biologic process is 
similar to that in rheumatoid arthritis, but in 
polymyalgia rheumatica it predominantly involves 
the proximal joints and not the distal peripheral 
joints.29
Dr. Harris: The patient had been having pain 
on swallowing for several months. Could this 
disease have been smoldering during that time 
before the acute presentation? Would this symp-
tom argue against a diagnosis of polymyalgia 
rheumatica?
Dr. Kay: The sore throat could have been a clue 
to the presence of giant-cell arteritis that involved 
her laryngeal arteries.
Dr. Finn: After the biopsy, the patient was started 
on prednisone (60 mg per day). She was referred to 
a neuro-ophthalmologist as well as a rheumatolo-
gist for assistance in corticosteroid management. 
An ophthalmologic examination was normal. She 
began taking trimethoprim–sulfamethoxazole 
prophylaxis and a proton-pump inhibitor for gas-
tric protection, and she was referred to a nutri-
tionist for management of her hyperglycemia. 
She was also referred to the bone clinic for con-
sideration of intravenous bisphosphonates, be-
cause she had been intolerant of alendronate 
when treated in the past. The prednisone dosage 
was tapered to 5 mg per day, but symptoms re-
curred; methotrexate (10 mg weekly) has recently 
been added. She currently feels well, 15 months 
after her original presentation.
A NAT OMIC A L DI AGNOSIS
Active giant-cell (temporal) arteritis.
No potential conflict of interest relevant to this article was 
reported.
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